SAN DIEGO--(BUSINESS WIRE)-- 858 Therapeutics, a clinical-stage biotechnology company, today announced preliminary safety and efficacy data from its ongoing, first-in-human Phase 1/2 trial of PARG inhibitor ETX-19477. These data will be presented in a poster session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday, May 30.

The ASCO abstract released today includes clinical data from 45 patients enrolled in the Phase 1a/b dose escalation and expansion portions of the study. The poster presentation will feature an expanded dataset of 53 patients, including seven patients who meet the eligibility criteria for the ongoing Phase 2 expansion cohorts in BRCA-mutated ovarian cancer and HR+/HER2- breast cancer. These criteria limit prior therapy to no more than five lines for ovarian cancer and no more than two lines for breast cancer. In this Phase 2-eligible subset, ETX-19477 demonstrated robust antitumor activity, with a 57% objective response rate (n=7). Durable RECIST responses were observed in both tumor types, providing the first clinical proof-of-concept for PARG inhibition in ovarian and breast cancer patients. ETX-19477 was generally well tolerated, with low rates of hematologic toxicity observed to date.

858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting

Business Wire